Effect of RAS Pathway Gene Mutations on Survival in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis - PubMed
3 days ago
- #MDS
- #survival analysis
- #RAS mutations
- RAS pathway gene mutations (NRAS, KRAS, PTPN11) negatively impact survival in myelodysplastic syndrome (MDS).
- KRAS mutations are associated with poorer overall survival (HR 1.66, 95% CI 1.32-2.08, P < 0.001).
- NRAS mutations lead to worse overall survival (HR 1.73, 95% CI 1.46-2.04, P < 0.001) and leukemia-free survival (HR 2.48, 95% CI 1.47-4.18, P < 0.001).
- PTPN11 mutations also decrease overall survival (HR 1.36, 95% CI 1.01-1.85, P = 0.046).
- The findings highlight the prognostic value of RAS mutations for refining MDS risk stratification models (IPSS-M, WPSS, MDAS).